Related Experiment Video
Updated: Jun 27, 2026
05:07
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
Published on: June 23, 2019
New 1H-pyrazole-4-carboxamides with antiplatelet activity
Klaus Rehse1, Joscha Kotthaus, Laleh Khadembashi
1Institut für Pharmazie, Freie Universität Berlin, Berlin, Germany. rehiwer@zedat.fu-berlin.de
Archiv Der Pharmazie
|December 4, 2008
Summary
Nine novel compounds were synthesized and tested for antiplatelet activity. Three compounds showed significant inhibition of platelet aggregation, with potent activity observed against adenosine diphosphate (ADP) and adrenaline.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Biochemistry
Background:
- Platelet aggregation is a key process in thrombosis.
- Developing novel antiplatelet agents is crucial for cardiovascular disease prevention.
- Existing antiplatelet drugs have limitations, necessitating new therapeutic options.
Purpose of the Study:
- To synthesize and evaluate novel chemical compounds for antiplatelet activity.
- To identify compounds effective against various platelet aggregation inducers.
- To determine the potency of synthesized compounds using IC50 values.
Main Methods:
- Synthesis of nine novel title compounds.
- Assessment of antiplatelet activity using the Born assay.
- Evaluation against collagen, adenosine diphosphate (ADP), adrenaline, and platelet activating factor (PAF) induced platelet aggregation.
Main Results:
- Three compounds (3b, 3e, 3i) demonstrated antiplatelet activity against collagen (IC50 < 100 microM).
- Compound 3b exhibited potent activity against ADP (IC50 = 9.4 nM).
- Compound 3i showed strong inhibition against adrenaline (IC50 = 5.8 nM).
- Compound 3e displayed remarkable activity against platelet activating factor (PAF) (IC50 = 0.45 nM).
Conclusions:
- The synthesized compounds show promising antiplatelet properties.
- Specific compounds are highly effective against key platelet aggregation pathways.
- These findings support further development of these compounds as potential antiplatelet therapeutics.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...